Trial Profile
A Randomized, Open-label, Multi-center, Phase 1b/2 Trial Evaluating the Safety and Efficacy of Intratumorally-administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who Are Candidates for CPI Therapy
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Ilixadencel (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Uterine cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ILIAD
- Sponsors Mendus
- 03 Dec 2021 Results published in the Media Release
- 03 Dec 2021 According to an Immunicum media release, updated data from this study will be provide in the first quarter of 2022
- 03 Dec 2021 Status changed from active, no longer recruiting to discontinued, according to an Immunicum media release.